non-small cell lung cancer
Hutchmed's Orpathys Approved in China for First-Line MET-Altered NSCLC
This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.
FDA Grants Priority Review to AstraZeneca, Daiichi Sankyo's Dato-DXd
In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.
CellCarta, Biofidelity Partner to Offer Lung Cancer Assay for Clinical Trials
CellCarta will validate Biofidelity's Aspyre Lung assay in its European and US labs and will hold nonexclusive rights to use it in global clinical trials.
Dizal Pharmaceutical Seeking FDA Approval for Sunvozertinib in EGFR Exon 20 Insertion-Mutated NSCLC
Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.
Innovent's Dovbleron Gains Approval in China for ROS1-Positive NSCLC
The firm also out-licensed its DLL3 antibody-drug conjugate candidate, IBI3009, to Roche this week.
Nov 19, 2024